NT-proBNP: A cardiac biomarker to assess prognosis in non-Hodgkin lymphoma

Gimeno, Eva; Gómez, Miquel; González, Juan R.; Comín, Josep; Alvarez‐Larrán, Alberto; Sánchez‐González, Blanca; Molina, Lluís; Domingo‐Domenech, Eva; García-Pallarols, Francesc; Pedro, Carmen; Abella, Eugènia; Vilaplana, Carles; Sanjosé, Sílvia de; Besses, Carlos; Salar, Antonio

doi:10.1016/j.leukres.2011.01.018

Cited by 30 publications

(26 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This characteristic may help identify vulnerable populations with pre-existing subclinical disease in addition to patients sensitive to chemotherapy induced damage [87,103,104]. …”

Section: Discussionmentioning

confidence: 99%

Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity

Christenson

James

Agrawal

et al. 2015

Clinical Biochemistry

104

View full text Add to dashboard Cite

Objectives To review the evidence for the use of various biomarkers in the detection of chemotherapy associated cardiac damage. Design and methods Pubmed.gov was queried using the search words chemotherapy and cardiac biomarkers with the filters of past 10 years, humans, and English language. An emphasis was placed on obtaining primary research articles looking at the utility of biomarkers for the detection of chemotherapy-mediated cardiac injury. Results Biomarkers may help identify patients undergoing treatment who are at high risk for cardiotoxicity and may assist in identification of a low risk cohort that does not necessitate continued intensive screening. cTn assays are the best studied biomarkers in this context and may represent a promising and potentially valuable modality for detecting cardiac toxicity in patients undergoing chemotherapy. Monitoring cTnI levels may provide information regarding the development of cardiac toxicity before left ventricular dysfunction becomes apparent on echocardiography or via clinical symptoms. A host of other biomarkers have been evaluated for their utility in the field of chemotherapy related cardiac toxicity with intermittent success; further trials are necessary to determine what role they may end up playing for prediction and prognostication in this setting. Conclusions Biomarkers represent an exciting potential complement or replacement for echocardiographic monitoring of chemotherapy related cardiac toxicity which may allow for earlier realization of the degree of cardiac damage occurring during treatment, creating the opportunity for more timely modulation of therapy.

show abstract

“…This characteristic may help identify vulnerable populations with pre-existing subclinical disease in addition to patients sensitive to chemotherapy induced damage [87,103,104]. …”

Section: Discussionmentioning

confidence: 99%

Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity

Christenson

James

Agrawal

et al. 2015

Clinical Biochemistry

104

View full text Add to dashboard Cite

show abstract

“…лечения доксорубицином не были значимо взаимо связаны с какими-либо ЭхоКГ изменениями через 4 года [12]. Было показано, что уровень NT-proBNP >900 пг/мл является предиктором высокого риска смерти от любых причин у пациентов, получавших терапию по поводу неходжкинской лимфомы, и предположили, что измерение уровней NT-proBNP следует учитывать при оценке риска у пациентов с неход жкинской лимфомой до начала химиотерапии [13]. В 2016г показано, что у пациентов, принимавших антрациклины, у которых уровень NT-proBNP был значительно повышен через 3 мес., 6 мес.…”

Section: таблицаunclassified

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy

Тепляков¹,

Шилов

Попова

et al. 2019

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Aim. To study the mechanisms, features of clinical manifestations and predicting of cardiotoxicity resulting from anthracycline chemotherapy.Material and methods. We examined 176 women with breast cancer who received anthracycline antibiotics as part of polychemotherapeutic (PCT) treatment. Patients were divided into 2 groups: with the development of cardiotoxic remodeling — group 1 (n=52) and with preserved heart function — group 2 (n=124). We conducted echocardiographic (EchoCG) tests before the start, during and after anthracycline chemotherapy. In the serum after the termination of PCT treatment, the concentrations of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and soluble Fas ligand (sFas-L) were determined.Results. Analysis of EchoCG parameters in patients after 12 months of PCT finish, showed a significant difference in the final systolic and end diastolic sizes, as well as a significant decrease in the left ventricular ejection fraction in group 1 compared with those before the start of treatment. A direct correlation was found between the end-systolic and end-diastolic volumes and inverse correlation between left ventricular ejection fraction and the resulting summary dose of doxorubicin. EchoCG changes in women of group 1 after the first course of PCT treatment were recorded in 49% of cases and 11% of cases — in group 2. The concentrations of sFas-L and NT-proBNP after PCT therapy finish in group 1 were significantly higher compared with group 2. Patients with significantly elevated NT-proBNP levels were had a high risk of heart disease developing during 12 months follow-up. A high concentration of NT-proBNP is a predictor of cardiovascular complications, which is more sensitive than EchoCG.Conclusion. Fas-associated apoptosis plays an important role in the pathogenesis of anthracycline cardiotoxicity. NT-proBNP may be an important biomarker for cardiotoxicity development, which already effective when EchoCG or clinical signs is absent.

show abstract

“…Natriuretic peptides biomarkers have been evaluated for risk stratification prior to and during therapy for cardiotoxicity. For instance, a single baseline NT-proBNP level of 900 pg/ml or more was associated with a higher risk of death from any cause in lymphoma patients treated with chemotherapy [52]. Evidences advocating the interest of natriuretic peptides monitoring during the course of chemotherapy exist [53][54][55][56].…”

Section: Circulating Biomarkersmentioning

confidence: 99%

Cardiac Imaging: Multimodality Advances and Surveillance Strategies in Detection of Cardiotoxicity

2017

View full text Add to dashboard Cite

Contemporary cancer management has increased the overall number of cancer survivors, but cardiotoxicity remains a subject of concern, which is a major cause of noncancer mortality among survivors. Among the potential cardiovascular complications, left ventricular (LV) systolic dysfunction is a poor prognostic factor. The importance of its early detection is based on the principle that the likelihood of response to heart failure (HF) treatment is temporally related to the initiation of HF treatment. For these reasons, cardiac monitoring is commonly applied in general practice, based on serial measurements of LV ejection fraction (LVEF); transthoracic echocardiography (TTE) is generally used. However, the LVEF, as a diagnostic and predictive parameter, has significant limitations, which calls for more effective multimodality imaging strategies. This approach requires further study, but there is increasing available data in the literature, encouraging the combination of multimodality imaging parameters and techniques for early cancer therapeutic-related cardiac dysfunction (CTRCD) detection.

show abstract

NT-proBNP: A cardiac biomarker to assess prognosis in non-Hodgkin lymphoma

Cited by 30 publications

References 38 publications

Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity

Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy

Cardiac Imaging: Multimodality Advances and Surveillance Strategies in Detection of Cardiotoxicity

Contact Info

Product

Resources

About